doi:10.1111/resp.12927 Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW
Those on the GLP-1 dulaglutide were found to have a 14% risk reduction of cognitive decline compared with those on placebo
If you exercise as part of your weight-loss plan, ensure you are fuelling appropriately around workouts
Use our internal guide: Reconstituting & Storage
Doses Studied in Clinical Trials Phase 2 trials have explored a wide range of weekly subcutaneous injections, with the following protocols tested: 1 mg per week Lowest dose, primarily studied for tolerability
Prior authorization requirements add another barrierphysicians must submit detailed documentation, wait for manual review, and often receive rejections that require appeals